Brazil's ANVISA: The Portuguese Language Barrier for Korean MedTech

This episode details the single most critical challenge for Korean medical device manufacturers entering Brazil: ANVISA's strict Portuguese-only documentation requirement. We explore why this is a major hurdle, how it differs from Korea's MFDS policies, and the significant risks of improper translation, including costly delays and registration failures. Key Questions: - Why is entering the Brazilian market uniquely challenging for Korean medical device companies? - What is ANVISA's strictest documentation requirement for all submissions? - How does Brazil's language policy for medical devices differ from Korea's MFDS? - What are the primary risks of improper translation for ANVISA submissions? - Why do general translation services often fail for MedTech regulatory documents? - What specific expertise is needed to successfully translate a technical dossier for Brazil? - How can Korean firms avoid costly delays and rejections related to documentation? Pure Global provides end-to-end regulatory solutions to help MedTech and IVD companies navigate complex market access challenges. Our team acts as your local representative in Brazil, ensuring all submissions meet ANVISA's stringent requirements. We leverage advanced AI tools to efficiently compile and manage technical dossiers, combined with expert review to ensure every document is accurately translated and compliant. This integrated approach streamlines your path to market, minimizing delays and costs. To learn how we can accelerate your entry into Brazil and over 30 other markets, visit us at https://pureglobal.com/, contact [e-mail], or explore our FREE AI tools and database at https://pureglobal.ai/.